ライフサイエンスコーパス: preinjection

1 ycine, with an ED50 = 31 mg/kg (i.p., 60 min preinjection).

2 ndent and PNA-mediated in the case of G3-HP1 preinjection.

3 ghout the nZVI/CMC affected area relative to preinjection abundance.

4 ed paired t test comparison of mean 5-minute preinjection and 5-minute postinjection physiological da

5 enabled real-time gas measurements (641 days preinjection and for 478 days postinjection).

6 They were hydrated preinjection and given a first bladder void break at 40

7 iotics only, and 0.04% among injections with preinjection and postinjection antibiotics (P = 0.20).

8 Use of preinjection and postinjection antibiotics was at the di

9 Comparison of mean 5-minute preinjection and postinjection physiologic parameters in

10 jections of isotonic MnCl(2), comparisons of preinjection and postinjection scans, and voxelwise stat

11 re, increased significantly less between the preinjection and recovery trials when scopolamine was ad

12 lwise statistical comparisons of at least 10 preinjection and two postinjection scans.

13 MRI scans were performed preinjection, and at 1, 2, and 4 days postinjection.

14 Preinjection antibiotic drops were used always or often

15 s associated with always or often instilling preinjection antibiotics (13.7% vs. 6.7%; P = 0.028), sc

16 antibiotic use, 0.08% among injections with preinjection antibiotics only, 0.06% among injections wi

17 s of 535 mum (range, 239-727 mum) and a mean preinjection best-corrected visual acuity (BCVA) of 63 a

18 ion was given 10 times in 9 eyes with a mean preinjection center field retinal thickness of 535 mum (

19 ly) significantly greater than corresponding preinjection CNR values (mean, 2.02 +/- 4.65, 0.02 +/- 0

20 signals remained essentially unaltered from preinjection conditions.

21 ased nearly 33-fold from baseline signals in preinjection images, and mean contrast between SLNs and

22 Preinjection in rats of a NMDA receptor antagonist MK-80

23 End points evaluated were maximum preinjection IOP during the 24-month treatment period; a

24 Preinjection IOP measurements for study eyes (n = 1125)

25 ab-treated eyes did not experience sustained preinjection IOP of 21 mmHg or more (>2 consecutive visi

26 more from baseline with concurrent absolute preinjection IOP of 21 mmHg or more or 25 mmHg or more;

27 treatment period; any occurrence of absolute preinjection IOP of 21 mmHg or more, 25 mmHg or more, or

28 , 60.1% to 70.9% of study eyes had a maximum preinjection IOP of less than 21 mmHg.

29 rsus 29.1% and 10.9% versus 5.1% had maximum preinjection IOPs of 21 mmHg or more or 25 mmHg or more,

30 ocular hypotony (P = 0.031), but returned to preinjection level after resolution of the hypotony afte

31 , indicate that methane increased 132% above preinjection levels based on isotopic labeling from D(2)

32 um Epo levels and increased hematocrits from preinjection levels of 48 +/- 0.4% to levels of 64 +/- 3

33 Mean preinjection logarithm of the minimal angle of resolutio

34 Preinjection medicinal therapy and ocular decompression

35 distribution of 125I-labeled dsFv, the HuTac preinjection method had a similar but longer lasting ben

36 one inner segment mosaics were compared with preinjection mosaics at multiple regions of interest.

37 c IOP-lowering with medicinal therapy and/or preinjection ocular decompression for patients with a hi

38 Blocking studies with preinjection of a CXCR4 inhibitor reduced (125)I-pentixa

39 were acquired at 1 and 2 h with or without a preinjection of a nonradioactive version of the fluoroph

40 transporter by PMA (100 nM) was abolished by preinjection of AbS4 (12 ng/ oocyte).

41 xenograft models with human lymphoma cells, preinjection of Ad35K(++) dramatically increased the the

42 g/kg bolus+0.08 mg/kg infusion over 30 min); preinjection of amphetamine (0.4 mg/kg, 5 min before rad

43 Preinjection of an NGF-neutralizing antibody or Trk inhi

44 Preinjection of blocking doses of unlabeled epibatidine,

45 to block the sIL-2Ralpha epitope and after a preinjection of bt-HuTac, followed by an avidin chase.

46 ects of reducing CLR on TxA ileitis by local preinjection of double-stranded RNAs.

47 Preinjection of either HuTac or bt-HuTac with avidin cha

48 In summary, our studies showed that preinjection of HuTac IgG can block the formation of com

49 ed dose of 125I-labeled antiTac dsFv after a preinjection of HuTac to block the sIL-2Ralpha epitope a

50 pressor response, which was abolished by ICV preinjection of losartan.

51 However, a preinjection of muscimol (a GABA(A) agonist) completely

52 )C]raclopride in three conditions: baseline; preinjection of nicotine (0.1 mg/kg bolus+0.08 mg/kg inf

53 nding of 11C-JHU75528 in vivo was blocked by preinjection of nonlabeled JHU75528.

54 Preinjection of oocytes with antisense oligonucleotide a

55 Preinjection of oocytes with pertussis toxin enhanced th

56 Preinjection of recombinant annexin IV blocked IR injury

57 Moreover, preinjection of the antioxidant GSH significantly inhibi

58 Preinjection of the blocking lanthanum-ESMA resulted in

59 performed in 2 atherosclerotic rabbits with preinjection of the CXCR4 inhibitor AMD3100.

60 alveolar TNF-alpha were blocked by alveolar preinjection of the intracellular Ca(2+) chelator BAPTA-

61 ctivity of (225)Ac-GPC3 ACC, with or without preinjection of the nonradioactive GPC3 ACC, in particip

62 hese beneficial effects were not achieved by preinjection of tPA, even at a 10-fold higher dose, whic

63 In vivo labeling was prevented by preinjection of WAY100635.

64 Preinjection of yohimbine, an alpha 2-adrenergic antagon

65 ic and povidone-iodine 5% without the use of preinjection or postinjection topical antibiotics.

66 fferences in pre- and postinjection pain and preinjection pain and post-MR imaging pain between the t

67 After adjusting for age, sex, and preinjection pain level, the mean differences in pre- an

68 Success was defined as improvement in preinjection plus disease or zone I stage 3 ROP by 5 day

69 The study protocol specified preinjection preparation to include use of a sterile lid

70 ing electronic health records, patients with preinjection preparation with PI or CHX were compiled re

71 n, e.g., protein, salts, and amino acids, no preinjection sample preparation steps (protein precipita

72 Values at preinjection time were used as baselines.

73 ed and reductions in plasma VEGF levels from preinjection to 2 weeks or 4 weeks.

74 (ECG) monitoring was performed from 3 hours preinjection to 24 hours postinjection.

75 o 8.5 +/- 4.1 (P = .00069, compared with the preinjection value) in the CTS patients.

76 jection peaked at 10 minutes and returned to preinjection values at 60 minutes.

77 All but 1 patient regained their preinjection visual acuity (average: 33 days; range: 7-7

78 Preinjection visual acuity ranged from 20/20 to counting

79 ation velocity (0.09 +/- 0.06 mu m/s, n = 25 preinjection vs 0.18 +/- 0.10 mu m/s, n = 61 postinjecti

80 Preinjection with a low inoculum of killed bacteria prot

81 Preinjection with an NOS inhibitor was partially protect

82 was manipulated prior to transplant through preinjection with beta-gal in complete Freund's adjuvant

83 ignal decay was observed in tumors only upon preinjection with EGFR-targeted conjugates.

84 Preinjection with SN50, a specific permeable recombinant

85 complete Freund's adjuvant (CFA) or through preinjection with soluble beta-gal i.v.

86 tantially improves tubular function, whereas preinjection with the NAD precursor nicotinamide (NAM) i